multiple sclerosis

Showing 15 posts of 105 posts found.


Teva hit by patent blow upon top-selling MS drug

January 31, 2017
Manufacturing and Production Mylan, Teva, generic, multiple sclerosis

Teva endured a rough ride in 2016, seeing its market value sink progressively over the course of the year. It …


Biogen shells out $1.25bn to protect best-selling MS drug

January 18, 2017
Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera

Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …


Roche’s ground-breaking MS drug delayed by manufacturing issues

December 22, 2016
Genentech, MS, Roche, multiple sclerosis

Roche has released both good and bad news just before Christmas. The good news is very good news for individuals …


Apitope reclaims multiple sclerosis treatment from Merck after 7 years

October 17, 2016
Sales and Marketing ATX-MS-1467, Apitope, Merck, multiple sclerosis

Apitope has announced it has reclaimed the global rights to its multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the …


Roche’s Ocrevus more effective than Merck’s Rebif, company claims

September 14, 2016
Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …


Positive Phase III results for Novartis MS drug

August 25, 2016
Research and Development Novartis, multiple sclerosis, phase III

Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, …


Teva loses patent protection on lucrative MS treatment

August 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …


Biogen and AbbVie’s Zinbryta gets European backing to treat multiple sclerosis

July 7, 2016
Research and Development, Sales and Marketing Biogen, drug approval, european union, multiple sclerosis, zinbryta

Biogen (Nasdaq: BIIB) and Abbvie’s (NYSE: ABBV) once-monthly Zinbryta (daclizumab) has been approved in European Union for treatment of multiple …

Roche says EMA accepts its marketing applications for Ocrevus to treat multiple sclerosis

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation

Cancer drugmaker Roche (SIX: ROG) said the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for its …


New high-risk treatment can halt MS, claim researchers

June 10, 2016
Research and Development multiple sclerosis, research

The results of a Phase II clinical trial, published in The Lancet, suggests that a new use of chemotherapy followed …


Biogen MS drug misses primary endpoint in Phase II trial

June 8, 2016
Research and Development Biogen, MS, multiple sclerosis, opicinumab

Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …


Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration

June 2, 2016
Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III

Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …


Biogen says European regulatory committee adopts positive view for Tysabri

June 1, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis

Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …


Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data

April 20, 2016
Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme

Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …


Novartis and Microsoft team up for Kinect collab

March 8, 2016
Manufacturing and Production, Research and Development Microsoft, Novartis, multiple sclerosis

Novartis has partnered with technology giant Microsoft; hoping to use its Kinect motion sensor to quantify whether its multiple sclerosis …

Latest content